Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 27Neoplasms 8Lung Neoplasms 6Neoplasms by Site 3Neoplasm Metastasis 3Lymphoma, Large-Cell, Anaplastic 3Hematologic Neoplasms 3Breast Neoplasms 3Brain Neoplasms 3Thyroid Neoplasms 2Sarcoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasms by Histologic Type 2Lymphoproliferative Disorders 2Gastrointestinal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Urinary Bladder Neoplasms 1Thyroid Cancer, Papillary 1Thoracic Neoplasms 1Solid Tumors 1Salivary Gland Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Rare Tumour 1Rare Tumor 1Prostatic Neoplasms 1Neuroendocrine Tumors 1Neuroblastoma 1

Interventions

Gemcitabine 92Cisplatin 70Oxaliplatin 37Capecitabine 37durvalumab 29Fluorouracil 26pembrolizumab 24Leucovorin 22S 1 (combination) 18Nivolumab 13Irinotecan 13Bevacizumab 13lenvatinib 12tremelimumab 10apatinib 8Trastuzumab 7Injections 7Albumin-Bound Paclitaxel 7130-nm albumin-bound paclitaxel 7Paclitaxel 6Immune Checkpoint Inhibitors 6Docetaxel 6titanium silicide 5surufatinib 5envafolimab 5camrelizumab 5atezolizumab 5Folfox protocol 5Drug Therapy 5Carboplatin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Biliary Tract Neoplasms × alectinib × Clear all
NCT02091141 2024-07-23

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Genentech, Inc.

Phase 2 Completed
673 enrolled 22 charts
GastrointestinalGenitourinary

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡